Arecor and medtronic diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery

Arecor therapeutics plc (“arecor” or the “company”) arecor and medtronic diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery medtronic to fund arecor's development of arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump cambridge, uk, 9 may 2024: arecor therapeutics plc (aim: arec), the biopharmaceutical group advancing today's therapies to enable healthier lives, today announced a research collaboration with medtronic plc (nyse: mdt), a global leader in healthcare technology, to develop a novel, high concentration, thermostable insulin for use by medtronic's diabetes business in a next-generation implantable pump. this new insulin has the potential to bring significant advancements in the current insulin treatment options for a small population of patients who have limited options for controlling their diabetes with traditional therapy.
MDT Ratings Summary
MDT Quant Ranking